Welcome to our dedicated page for BIOHARVEST SCIENCES SEC filings (Ticker: BHST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BIOHARVEST SCIENCES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BIOHARVEST SCIENCES's regulatory disclosures and financial reporting.
BioHarvest Sciences reported Q2 2026 revenue of $8.8 million, up 3.8% year-over-year, with a 58% gross margin. Operating loss was $2.5 million and net loss was $3.7 million, or $0.17 per share. Adjusted EBITDA loss was $1.6 million.
The company secured its first CDMO manufacturing and supply agreement with a UAE-based fragrance customer, supporting an anticipated 20 tons of rare botanical fragrance production over two years, with initial limited production expected as early as the first half of 2027. Cash and cash equivalents plus bank deposits totaled $16.2 million as of June 30, 2026.
Guidance for 2026 was revised: CDMO revenue is now expected at $4–$5 million with EBITDA loss reduced to $1.5–$2.5 million, while VINIA D2C revenue is lowered to $33–$35 million and EBITDA is now forecast as a $1.5–$2.5 million loss as spending shifts to manufacturing capacity. Consolidated EBITDA loss is projected at $3–$5 million.
BioHarvest Sciences Inc. reported H1 2026 revenue of $17,344 thousand, up modestly year over year, with 94% from its Products Business Unit and the balance from CDMO Services. Gross margin was 58%, generating a net loss of $6,356 thousand (loss per share $0.28).
Cash and cash equivalents were $15,211 thousand and bank deposits $1,012 thousand as of June 30, 2026, supporting working capital of $14,504 thousand. Some high‑rate short-term loans and a convertible facility were fully repaid, while investor notes totaling $2,662 thousand remain outstanding.
The company flags substantial doubt about its ability to continue as a going concern due to ongoing losses and financing uncertainty, although management expects existing liquidity and operations to fund at least 12 months. Operations are organized into Products and CDMO Services business units; in H1 2026, Products revenue grew 4% and CDMO Services 43% versus the prior year.
BioHarvest Sciences Inc. will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston, held August 11-13, 2026. Chief Executive Officer Zaki Rakib is scheduled to deliver a company presentation on Wednesday, August 12, 2026, at 1:00 p.m. and will also hold one-on-one investor meetings on August 11-12.
The presentation will be available via a publicly accessible live webcast for online pre-registrants, while in-person attendance requires conference registration. BioHarvest describes itself as a leader in Botanical Synthesis, operating both as a CDMO for plant-based compounds and as a developer of proprietary nutraceutical health and wellness products.
BioHarvest Sciences Inc. plans to report its second quarter 2026 financial results before the market opens on August 11, 2026, and will host a conference call and webcast at 8:00 AM Eastern Time to review results and provide a business update.
CEO Zaki Rakib, approaching his first 100 days in the role, expects to discuss the company’s 2026 strategy and growth plan. BioHarvest describes itself as a leader in Botanical Synthesis, operating as a CDMO for plant-based compounds and as a developer of proprietary nutraceutical products.
BioHarvest Sciences Inc. reported that the Israel Innovation Authority approved a 4.33 million NIS (approximately USD $1.4 million) grant, structured as a non-dilutive, zero-interest loan. Repayment is contingent on predefined commercial milestones and is expected to come solely from revenues generated by the funded project, with no equity or equity-linked securities issued.
The funding supports a new research initiative that integrates advanced data science, machine learning, computer vision and high-throughput digital sensing into BioHarvest’s plant cell culture workflows, aiming to shift from trial-and-error to predictive, data-driven optimization and higher active metabolite yields. This is the second Israel Innovation Authority grant to BioHarvest this year, with the first focused on automating the manufacturing facility and the new grant targeting the early-stage R&D pipeline through predictive AI, together spanning discovery through to large-scale production.
BioHarvest Sciences Inc. reports that the Israel Innovation Authority has approved a 4.33 million NIS (approximately USD $1.4 million) non-dilutive grant to fund an AI-driven plant-cell synthesis research program. The funding will integrate data science, machine learning, computer vision and high-throughput digital sensing into its biological development workflows.
The project aims to replace trial-and-error plant cell culture with a predictive, data-focused platform that maximizes active metabolite yields for CDMO customers and partners. The grant is structured as a zero-interest loan, repayable only from future revenues generated by the funded project, and involves no equity or equity-linked issuance. It is the second Israel Innovation Authority grant this year, complementing a prior award focused on automating and scaling manufacturing operations.
BioHarvest Sciences Inc. filed a Form 6-K announcing it will present at the 2026 BIO International Convention in San Diego from June 22-25. The company’s session is scheduled for Wednesday, June 24 at 11:45 in Theater 3.
The presentation will highlight BioHarvest’s proprietary Botanical Synthesis™ platform, which produces plant-derived compounds with pharmaceutical-grade precision and commercial scalability. Management emphasizes recent capability expansion, increased partner engagement, and strategic initiatives aimed at collaborations with pharmaceutical and life science companies through its CDMO and nutraceutical businesses.
BioHarvest Sciences Inc. has called its annual general meeting for June 25, 2026 in Vancouver. Shareholders will vote to set the board size at seven directors, elect four nominees to staggered three- and one-year terms, and ratify Ziv Haft, Certified Public Accountants (Isr), BDO Member Firm, as auditor. They will also receive the audited financial statements for the year ended December 31, 2025.
The circular explains proxy and voting procedures for registered and beneficial owners and outlines executive and director compensation, including salary, option and RSU elements under the 2025 Equity Incentive Plan. As of the May 19, 2026 record date, 22,667,842 common shares were outstanding, with Vivien Rakib holding 3,041,674 shares, or 13.42%. The document also details the fully independent audit committee, its charter, and audit and related fees for 2024 and 2025.
BioHarvest Sciences reported first quarter 2026 revenue of $8.5 million, up 8% year over year, with gross margin improving to 59% from 58%. The business is managed through a CDMO services segment and a direct-to-consumer products segment.
Operating loss was $1.8 million, slightly wider than last year, and net loss was $2.6 million, or $0.11 per share. Adjusted EBITDA loss held roughly flat at $1.2 million, reflecting continued investment in growth rather than profitability.
On the CDMO side, BioHarvest advanced two Botanical Synthesis programs to Stage 2, with combined agreements valued at over $2 million, including a $1.2 million fragrance contract and a saffron program valued at over $1 million. On the D2C side, the VINIA brand reached 90,000 active users and its Blood Flow Hydration product generated $920,000 in cumulative revenue since launch, supported by a shift from TV to digital marketing. Cash and bank deposits totaled $20.2 million as of March 31, 2026.
BioHarvest Sciences Inc. reported Q1 2026 revenue of $8,507 thousand, up from $7,860 thousand a year earlier, driven mainly by its Products unit and strong CDMO services growth. Gross margin was about 59%, similar to last year, but the company still posted a net loss of $2,641 thousand, slightly larger than the prior period.
Cash and cash equivalents were $19,167 thousand as of March 31, 2026, giving positive working capital of $18,742 thousand. Management nonetheless discloses that recurring losses, ongoing investment needs and reliance on future financing raise substantial doubt about the company’s ability to continue as a going concern, even though they believe current resources support operations for at least the next 12 months.